National Median Cost for C-Section Covered by Commercial Insurance Is More Than $19,000
NEW YORK, June 17, 2025 /PRNewswire/ -- The national median1 total cost for a C-section for commercially insured patients staying in network is more than $19,000, and for vaginal delivery it is more than $15,000, according to FAIR Health's Cost of Giving Birth Tracker. These figures reflect the national median allowed (in-network) amount2 for the procedures, and include both the portion to be paid by the plan member and the portion to be paid by the plan.
The Cost of Giving Birth Tracker is a free, interactive tool, updated today, that tracks the cost of giving birth state by state. Available on FAIR Health's website fairhealth.org, the Cost of Giving Birth Tracker consists of heat maps that show state-specific and national median charge3 and allowed amounts for vaginal deliveries and C-sections. The tool draws on the national, independent nonprofit FAIR Health's database of over 51 billion commercial healthcare claim records—the largest such repository in the country.
The Cost of Giving Birth Tracker includes inpatient and outpatient facility and professional costs. Services include the delivery itself (e.g., pharmacy, nursery, labor and delivery room, medical and surgical supplies, room and board for the mother), anesthesia, fetal nonstress tests, ultrasounds, laboratory work and a breast pump. The data come from the September 2024 release of the vaginal delivery and C-section FH® Total Treatment Cost benchmarks.
Among the findings of the Cost of Giving Birth Tracker:
Alaska is the state with the highest median allowed amount for vaginal deliveries, $29,152.08, followed by (in order from highest to lowest) New York, New Jersey, Connecticut and California.
Alaska also has the highest median allowed amount for C-sections, $39,531.62, followed by Maine, Vermont, Oregon and New Jersey.
Mississippi has the lowest median allowed amount for vaginal deliveries, $9,847.37, followed by (in order from lowest to highest) Alabama, Arkansas, Louisiana and Missouri.
Mississippi also has the lowest median allowed amount for C-sections, $11,110.18, followed by Alabama, Arkansas, Louisiana and Tennessee.
The Cost of Giving Birth Tracker is one of FAIR Health's series of FH® Trackers offering geographic windows into healthcare data. The series also includes the Monthly Telehealth Regional Tracker, which tracks telehealth utilization by region across the nation, and the Opioid Tracker, which tracks opioid abuse and dependence.
For the Cost of Giving Birth Tracker, click here.
Follow us on X @FAIRHealth
About FAIR Health FAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation's largest collection of commercial healthcare claims data, which includes over 51 billion claim records and is growing at a rate of about 4 billion claim records a year. FAIR Health licenses its commercial data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D, which accounts for a separate collection of over 51 billion claim records; FAIR Health includes among the commercial claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health's systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 Type 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers' compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger's Personal Finance. For more information on FAIR Health, visit fairhealth.org.
Contact: Rachel Kent Executive Director of Communications and Marketing FAIR Health 646-396-0795 rkent@fairhealth.org
1 A median is the midpoint of the distribution of values below and above which there is an equal number of values. 2 An allowed amount is the total fee negotiated between an insurance plan and a provider for an in-network service. 3 A charge amount is the amount charged to a patient who is uninsured or obtaining an out-of-network service.
View original content to download multimedia:https://www.prnewswire.com/news-releases/national-median-cost-for-c-section-covered-by-commercial-insurance-is-more-than-19-000--302463227.html
SOURCE FAIR Health
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Global Healthcare Gets a 6G Boost: Market to Grow at 77.9% CAGR Through 2040
"This report explores how 6G is poised to reshape global healthcare through innovations in remote patient monitoring, AR/VR diagnostics, robotic surgeries, and smart hospital infrastructure, powered by ultra-low latency, AI integration, and massive device connectivity." BOSTON, Aug. 20, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "6G in Healthcare: Global Market" is projected to reach $194 billion by the end of 2040 with a CAGR of 77.9% from 2031 to 2040. The report analyzes the global 6G market in healthcare, exploring trends, challenges, and growth drivers. It segments the market by component, application, connectivity, end user, and region, covering the major areas of North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. Additionally, it evaluates the competitive landscape by ranking leading companies and profiling major players. This report is especially relevant now as the global momentum toward digital healthcare transformation continues to grow, and research into 6G technology rapidly advances. It provides timely insights into how 6G is poised to revolutionize healthcare by enhancing delivery, boosting efficiency, and driving innovation. For early adopters and stakeholders, understanding these developments is crucial to staying ahead in a highly competitive and evolving landscape. The factors driving the market's growth include: Rising Demand for Enhanced Healthcare Services and Efficiency: Healthcare systems are under pressure to deliver faster, more personalized, and cost-effective care. 6G can support this by enabling real-time diagnostics, AI-powered decision-making, and seamless telemedicine experiences, ultimately improving service quality and operational efficiency. Growing Adoption of IoT and Connected Devices in Healthcare: The increasing use of wearables, smart medical equipment, and remote monitoring tools is transforming healthcare. 6G will enhance these technologies by offering faster data transmission, better connectivity, and improved energy efficiency, creating a smarter and more responsive healthcare ecosystem. Need for Ultra-Reliable and Low-Latency Communication for Critical Applications: In life-critical scenarios like remote surgeries or emergency response, reliability and speed are essential. 6G's ultra-low latency and high reliability ensure uninterrupted, secure communication, making it ideal for mission-critical healthcare applications. Request a sample copy of the global market trends for 6G in healthcare report. Report Synopsis Report Metric Details Base year considered 2030 Forecast period considered 2031-2040 Base year market size $664.2 million Market size forecast $194.0 billion Growth rate CAGR of 77.9% from 2031 to 2040 Segments covered Component, Application, Connectivity Type, End User, and Region Regions covered North America, Europe, Asia-Pacific, South America, and the Middle East and Africa (MEA) Countries covered U.S., Canada, Mexico, Brazil, Argentina, Japan, China, India, South Korea, Australia, Rest of Asia-Pacific, Germany, U.K., France, Italy, Spain, Rest of Europe, the Middle East, and Africa Market drivers • Rising demand for enhanced healthcare services and efficiency. • Growing adoption of IoT and connected devices in healthcare. • Need for ultra-reliable and low-latency communication for critical applications. Interesting facts: 6G technology is expected to be 100 times faster than 5G, enabling real-time remote surgeries, seamless medical data transmission, and continuous biometric streaming via wearables for predictive healthcare analytics. It will also support digital twins, the virtual patient models that allow doctors to simulate treatments before applying them in real life. The integration of AI and 6G could dramatically reduce emergency response times through intelligent, connected systems. South Korea and China are among the countries already investing in national initiatives to lead 6G healthcare innovations by 2030. The report addresses the following questions: 1. What are the projected size and growth rate of the market? The global market for 6G in healthcare is projected to reach $194 billion by the end of 2040, with a CAGR of 77.9%. 2. Which factors are driving the growth of the market? The growth of 6G in the healthcare market is driven by increasing demand for real-time patient monitoring and data-intensive applications. Advances in AI and IoMT are enhancing diagnostic precision and care delivery through ultra-fast connectivity. The rising adoption of telehealth and remote surgeries requires the low latency and high reliability that 6G offers. Growing investments in smart hospitals and digital infrastructure further propel the market expansion for 6G. 3. Which market segments are covered in the report? The market in this report is segmented by component, application, connectivity, and end user. 4. Which component segment will be dominant through 2040? The hardware segment will dominate the market for 6G in healthcare. 5. Which region has the highest market share? The North America market for 6G in healthcare was valued at $201.3 million in 2030 and is projected to reach $52.6 billion in 2040, at a CAGR of 76.0% during the forecast period. Market leaders include: APPLE AT&T CISCO SYSTEMS HUAWEI TECHNOLOGIES CO. LTD. INTEL MICROSOFT NOKIA QUALCOMM TECHNOLOGIES INC. SAMSUNG SIEMENS HEALTHINEERS AG Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301 For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Signos Unveils First Ever FDA-Cleared Glucose Monitoring Breakthrough for Weight Management, Enabling Millions of Americans to Take Control of Their Health
PALO ALTO, Calif., Aug. 20, 2025 /PRNewswire/ -- Signos, a purpose-driven metabolic health platform committed to transforming lives through personalized, real-time insights, today announced the launch of Signos Glucose Monitoring System, the first ever FDA-cleared, over-the-counter glucose monitoring system for weight management. At a time when obesity and disease threaten the well-being of millions, Signos is leading the movement to put metabolic health back into the hands of individuals. By integrating Stelo by Dexcom glucose biosensor with an AI-powered platform for deciphering unique metabolisms, Signos enables people to see how food choices, timing, activity, stress, and even sleep affect their bodies in real time — equipping them with the information required to seize their health and make decisions backed by their own biology. "This is more than a product launch — it's a mission," said Sharam Fouladgar-Mercer, CEO and Founder of Signos. "Everyone deserves access to insights that help them live healthier, longer, more vibrant lives. Signos isn't just about data; it's about giving people ownership over their health and weight journeys in a way never before seen." Key Features and Purpose-Driven Benefits: Igniting the Metabolic Movement with Personalized Data: By tapping into the body's own signals, Signos equips individuals with tools to improve sleep, manage weight, and reduce the risk of chronic disease — not through restriction, but through understanding. Personalized, AI-Driven Insights: Signos translates glucose fluctuations into easy-to-follow, personalized recommendations — transforming raw data into actionable guidance for building healthier everyday habits. Total Body Intelligence: Signos helps users understand how their bodies respond to meals, workouts, sleep, and stress, creating a holistic picture of personal health. Expert Metabolic Monitoring: Signos removes barriers and puts powerful glucose insights into the hands of millions without the need for prescriptions, inflated prices, or hidden hoops. It's real-time metabolic health, made truly accessible. The need for accessible, effective metabolic health solutions has never been greater. With 73.6% of U.S. adults classified as overweight or obese, 88% of Americans classified as metabolically unhealthy, and global diabetes diagnoses projected to reach 1.3 billion by 2050, Signos offers a proactive solution grounded in science and is changing the trajectory of metabolic health by intervening early and guiding users toward meaningful, lasting lifestyle changes. The company aims to help millions monitor their metabolic health and build better habits by leveraging insights based on glucose, the body's primary energy source. Raven-Symoné, actress and advisor, shared, "I've been using Signos for years now and no matter my mental ups and downs it is there to keep me in reality. The reality is things change, levels change, but if you keep an eye on the overall picture you can keep your health in the green. Signos gives me the confidence to enjoy life while being mindful of my body and what it needs." Signos is available now, offering individuals everywhere a revolutionary way to monitor glucose, unlock personalized insights, and take control of their metabolism to build a sustainably healthier life — all from the convenience of their smartphone. For more information, visit View original content to download multimedia: SOURCE Signos
Yahoo
3 hours ago
- Yahoo
Human Microbiome Market worth $7.09 billion by 2031 with 31.0% CAGR
DELRAY BEACH, Fla., Aug. 20, 2025 /PRNewswire/ -- The global Human Microbiome Market, valued at US$0.91 billion in 2024, stood at US$1.40 billion in 2025 and is projected to advance at a resilient CAGR of 31.0% from 2025 to 2031, culminating in a forecasted valuation of US$7.09 billion by the end of the period. The primary drivers behind the expansion of this industry are the technological advancement in microbiome sequencing, the collaborative efforts between the microbiome industry, organizations, and academia for microbiome research, and the increase in the number of startups and SMEs exploring the microbiome niche, and further opportunities such as the increase in demand for personalized medicine and the emergence of synbiotics may help drive the human microbiome market. Download PDF Brochure: Browse in-depth TOC on "Human Microbiome Market" 416 - Tables64 - Figures371 - Pages By type, bacterial consortia transplantation (BCT)/ fecal microbiota transplantation (FMT), live bacteria products, and others segment the human microbiome market. Live bacteria products accounted for the largest share of the human microbiome market in 2024. This category includes probiotics and synbiotics, which are widely used in consumer health supplements and emerging therapeutic applications. The dominance of live bacteria products is driven by strong consumer demand for digestive and immune health solutions, along with increasing clinical validation of specific bacterial strains. These products are often easier to formulate, regulate, and distribute compared to more complex microbiome therapies, allowing for faster commercialization. Additionally, ongoing advancements in encapsulation and delivery technologies have improved bacterial stability and survivability through the gastrointestinal tract, enhancing their effectiveness. The growing focus on personalized nutrition and preventive health has further expanded the adoption of live bacteria products across various age groups and health segments. Fecal microbiota transplantation/biological combination therapies (FMT/BCT) accounted for the second-largest share, supported by approved drugs such as VOWST and Rebyota for recurrent Clostridioides difficile infection. By end users, the human microbiome market is segmented by end users, hospitals & clinics, long-term care facilities, and other end users. Hospitals and clinics accounted for the largest share of the human microbiome market in 2024. This is largely due to their critical role in administering, monitoring, and regulating microbiome-based therapeutics, particularly those targeting infectious and gastrointestinal conditions. Approved products such as VOWST and Rebyota, used to prevent recurrent Clostridioides difficile infection, are typically prescribed and delivered in clinical settings under medical supervision. These facilities provide the necessary infrastructure for managing live microbial therapies, which may require cold-chain storage, specialized handling, and follow-up care. Hospitals and clinics are also key sites for clinical research, including patient enrollment for microbiome-based drug trials and real-world evidence studies. Their involvement enables close monitoring of patient outcomes, adverse events, and long-term therapeutic effects, all of which are essential for the advancement of microbiome science and regulatory approval processes. Moreover, the rising prevalence of chronic conditions linked to microbiome imbalance, such as inflammatory bowel disease and metabolic disorders, has led to increased hospital-based consultations and treatment protocols involving microbiome interventions. The presence of trained healthcare professionals, diagnostic tools, and institutional trust further supports the strong uptake of microbiome products within hospital and clinical environments. By geography, in 2024, North America accounted for the largest share of the human microbiome market. This leading position is supported by a well-established biotechnology ecosystem, strong research and development infrastructure, and the presence of major market players such as Seres Therapeutics, Seed Health, and IFF. The region has seen significant regulatory progress, with the US FDA approving the first microbiome-based drugs, including Rebyota and VOWST, for the prevention of recurrent Clostridioides difficile infection. These approvals have encouraged further investment in microbiome therapeutics and supplements. North America also has high adoption rates for probiotics, prebiotics, and synbiotics, driven by increasing consumer awareness of gut health and preventive wellness. The region supports a growing number of clinical trials and academic collaborations focused on the role of microbiomes in conditions such as gastrointestinal diseases, metabolic disorders, and cancer. Additionally, favorable healthcare spending, innovation funding, and regulatory clarity continue attracting startups and established firms. These combined factors reinforce the dominant position of North America in the global human microbiome market. Request Sample Pages : Some of the leading players in the market include Seres Therapeutics (US), Ferring B.V. (Switzerland), BiomeBank (Australia), Seed Health, Inc. (US), International Flavors & Fragrances Inc. (US), Pendulum (US), Biohm Technologies (US), Actial Farmaceutica Srl (Italy), OptiBiotix Health Plc (UK), resbiotic (US), Infinant Health Inc. (US), BioGaia (Sweden), and ExeGi Pharma (US), among others. Seres Therapeutics (US): Seres Therapeutics is one of the emerging players in the human microbiome market. The company's microbiome therapeutics platform significantly reduces the time typically required to advance therapeutics to the clinic and, ultimately, to the market. The company focuses on R&D to launch advanced products in the market. Its R&D expenses were USD 64.6 million for the year ending December 31, 2024. It specializes in creating oral live biotherapeutic products with defined bacterial consortia intended to modulate the human microbiome. Its lead product, VOWST (formerly SER-109), received FDA approval in April 2023 to prevent recurrent Clostridioides difficile infection. VOWST is the first FDA-approved orally administered microbiome therapeutic. In 2023, Seres Therapeutics implemented organizational changes, including workforce reductions and a narrowed R&D focus. In June 2024, the company entered into an agreement with Nestlé Health Science to transfer full commercialization rights for VOWST. The company continues to pursue clinical development of its remaining programs and maintains collaborations with academic and industry partners. FERRING B.V. (SWITZERLAND) Ferring Pharmaceuticals is a biopharmaceutical company involved in the development of microbiome-based therapeutics. The company operates in multiple therapeutic areas, including reproductive medicine, maternal health, gastroenterology, and urology. Ferring engages in internal research and external partnerships in the microbiome space. It acquired Rebiotix, a company developing live biotherapeutic products targeting the human microbiome. The company developed Rebyota, a fecal microbiota-based therapeutic indicated for preventing recurrent Clostridioides difficile infection. The product received FDA approval in November 2022 and is administered via enema. It has also collaborated with organizations such as Karolinska Institutet, Intralytix, MyBiotics, and PharmaBiome to explore live microbial consortia, bacteriophage-based therapies, and microbiome diagnostics. The company maintains manufacturing and R&D operations in various regions and continues to advance its microbiome programs across therapeutic categories through preclinical and clinical development stages. International Flavors & Fragrances Inc. (US) International Flavors & Fragrances (IFF) operates in the fields of flavor, fragrance, nutrition, and biosciences, with a growing focus on microbiome-based ingredients. The company has developed capabilities in precision fermentation and microbial strain engineering, enabling the industrial-scale production of next-generation probiotics, including strict anaerobes like Akkermansia. These technologies support ingredient development for applications in human and pet health, food, and supplements. IFF's HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets like Brazil for reducing eczema risk in infants and pregnant women. IFF offers products such as HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The HOWARU brand includes clinically studied probiotic strains such as HN001, HN019, NCFM, Bi-07, and Bl-04. These strains are formulated for specific health outcomes, including immune support, digestive health, stress response, early life development, and healthy aging. HN001 has regulatory recognition in markets such as Brazil for reducing eczema risk in infants and pregnant women. IFF offers products like HOWARU Protect and HOWARU Restore, each targeting different stages of life or health needs. The microbiome innovation of IFF is supported by ongoing collaborations and a broader portfolio in synthetic biology, enabling the development of functional ingredients across consumer and health product categories. For more information, Inquire Now! Related Reports: Clinical Microbiology Market High Throughput Screening Market Microbiome Sequencing Services Market Rapid Microbiology Testing Market Laboratory Proficiency Testing Market Get access to the latest updates on Human Microbiome Companies and Human Microbiome Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets 登入存取你的投資組合